CASI Pharmaceuticals, Inc. (CASI)
| Market Cap | 122.90M |
| Revenue (ttm) | 25.83M |
| Net Income (ttm) | -45.25M |
| Shares Out | 139.80M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 748,416 |
| Open | 0.869 |
| Previous Close | 0.860 |
| Day's Range | 0.847 - 0.900 |
| 52-Week Range | 0.760 - 3.900 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 4.45 (+406.2%) |
| Earnings Date | Nov 12, 2021 |
About CASI
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute ly...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CASI stock is "Strong Buy." The 12-month stock price forecast is 4.45, which is an increase of 406.20% from the latest price.
News
CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference
ROCKVILLE, Md., and BEIJING, Nov. 15, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...
CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results
ROCKVILLE, Md. and BEIJING, Nov. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...
CASI Pharmaceuticals Earnings Preview
CASI Pharmaceuticals (NASDAQ:CASI) is set to give its latest quarterly earnings report on Friday, 2021-11-12. Here's what investors need to know before the announcement.
CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021
ROCKVILLE, Md., and BEIJING, Nov. 5, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...
CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021
ROCKVILLE, Md. and BEIJING, Nov. 2, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) F...
ROCKVILLE, Md. and BEIJING, Oct. 25, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...
CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy?
CASI Pharma (CASI) has been struggling lately, but the selling pressure may be coming to an end soon.
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
ROCKVILLE, Md. and BEIJING, Sept.
Penny Stocks For Your Biotech Watch List In September 2021
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Trending Penny Stocks To Buy For Under $3 Right Now
Are these penny stocks worth the risk? The post Trending Penny Stocks To Buy For Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 44.44% and 16.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results
ROCKVILLE, Md. and BEIJING, Aug. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...
CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021
ROCKVILLE, Md. and BEIJING, Aug. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...
Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for
CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractor...
ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference
ROCKVILLE, Md. and BEIJING, May 27, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
CASI Pharmaceuticals: Q1 Earnings Insights
Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 22.22% year over year to ($0.11),...
CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
ROCKVILLE, Md. and BEIJING, May 13, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021
ROCKVILLE, Md. and BEIJING, May 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383%
Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
CASI Pharmaceuticals Announces Full Year 2020 Financial Results
ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...
Why CASI Pharmaceuticals Is Crashing Today
Investors don't like that the company is hitting up the market for more cash.
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock
ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
ROCKVILLE, Md. and BEIJING, March 23, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...